How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

365 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. 24-hr Intraocular Pressure Control With SIMBRINZA ®

Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) 24-hr Intraocular Pressure Control With SIMBRINZA ® 24-hr Intraocular Pressure Control With SIMBRINZA ® - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 24-hr Intraocular Pressure Control With SIMBRINZA ®

2016 Clinical Trials

22. Is intraocular pressure the only important postoperative variable? The role of first day postoperative review after vitrectomy (PubMed)

Hospital, Guntur, India. eng Letter 2016 02 05 England Eye (Lond) 8703986 0950-222X 0 Carbonic Anhydrase Inhibitors IM Eye (Lond). 2016 May;30(5):768 26846594 Carbonic Anhydrase Inhibitors therapeutic use Endotamponade Glaucoma prevention & control Humans Intraocular Pressure drug effects physiology Patient Care Management Postoperative Period Tonometry, Ocular Vitrectomy 2016 2 6 6 0 2016 2 6 6 0 2017 2 2 6 0 ppublish 26846595 eye20164 10.1038/eye.2016.4 PMC4869145 Arch Ophthalmol. 2004 May;122(5):705 (...) Is intraocular pressure the only important postoperative variable? The role of first day postoperative review after vitrectomy 26846595 2017 02 01 2018 11 13 1476-5454 30 5 2016 05 Eye (London, England) Eye (Lond) Is intraocular pressure the only important postoperative variable? The role of first day postoperative review after vitrectomy. 767-8 10.1038/eye.2016.4 Harshey K B KB Vitreo-Retina and Ocular Oncology, Sankara Eye Hospital, Bangalore, India. Madhukumar R R Vitreo-Retina, Sankara Eye

Full Text available with Trip Pro

2016 Eye

23. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. (PubMed)

Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. To perform a meta-analysis to estimate the intraocular pressure (IOP)-lowering efficacy and safety of alpha(2)-adrenergic agonists (AAs), beta-adrenergic antagonists (BBs), and topical carbonic anhydrase inhibitors (TCAIs) when used in combination with a prostaglandin analog (PGA).MEDLINE, Embase, and the Cochrane Controlled

Full Text available with Trip Pro

2010 Archives of ophthalmology

24. Does Oral Acetaminophen Lower Intraocular Pressure?

Study Description Go to Brief Summary: - Lowering intraocular pressure is the only proven treatment for glaucoma. Medications, almost always in the form of eye drops, are a mainstay for lowering intraocular pressure. Eye drops have the disadvantage of being difficult to administer and can have adverse effects on the surface of the eye and the surrounding tissues. Lowering intraocular pressure can be accomplished with oral carbonic anhydrase inhibitors, but the many systemic side effects (...) Does Oral Acetaminophen Lower Intraocular Pressure? Does Oral Acetaminophen Lower Intraocular Pressure? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Does Oral Acetaminophen Lower Intraocular Pressure

2015 Clinical Trials

25. Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection

Natriuretic Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2014 Clinical Trials

26. Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure

to control intraocular pressure Currently on oral carbonic anhydrase inhibitor for intraocular pressure control Single eye, the other eye blind from any cause Related to surgical procedures Prior laser trabeculoplasty Prior glaucoma surgery Prior retinal surgery Underwent less than 3-month cataract extraction Potential need for other ocular surgery within the 2-3-month follow-up period since enrollment Related to underlying and ocular history History of diabetic retinopathy staged as severe non (...) Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2014 Clinical Trials

27. Comparison of IOP (Intraocular Pressure)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Carbonic Anhydrase Inhibitors (...) Comparison of IOP (Intraocular Pressure)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2014 Clinical Trials

28. The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

blocker therapy Diagnosis of any other form of glaucoma other than open-angle Schaffer angle grade < 2 in either eye by gonioscopy Intraocular surgery within 6 months or laser within 3 months Inability to safely discontinue all ocular medications for 6 weeks Patients who smoke or have irregular daily sleep patterns History of allergy or intolerance to topical carbonic anhydrase inhibitors, or alpha-agonists Patients who have started or changed glucocorticoids therapy in the last 3 months Patients who (...) The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2014 Clinical Trials

29. Intraocular pressure efficacy of glaucoma medications versus placebo in phase II compared to later phase trials. (PubMed)

than placebo in phase III (p=0.007) and IV (p=0.02). Generally, for prostaglandins, β blockers and carbonic anhydrase inhibitors for the morning trough and diurnal curve there was no difference in pressure reduction from baseline for phase II compared to phase III or IV (p≥0.23). In contrast, where comparisons were available for the decrease in pressure from placebo there were differences for phase II compared to phase III and phase IV (p≤0.02). This study suggests that in early phase glaucoma (...) Intraocular pressure efficacy of glaucoma medications versus placebo in phase II compared to later phase trials. This review aimed to compare the predictive value between the untreated reduction in intraocular pressure (IOP) from baseline or placebo measured in early phase clinical trials to phase III and IV results for glaucoma medicines. Published, placebo-controlled, randomised, parallel, single-masked or double-masked clinical trials with at least one phase II, III and IV study available

2013 British Journal of Ophthalmology

30. Evaluation of Intraocular Pressure Using Simbrinzaâ„¢ in Patients With Open-Angle Glaucoma or Ocular Hypertension

Cardiovascular Diseases Eye Diseases Timolol Brimonidine Tartrate Maleic acid Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors (...) Evaluation of Intraocular Pressure Using Simbrinzaâ„¢ in Patients With Open-Angle Glaucoma or Ocular Hypertension Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2013 Clinical Trials

31. Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

eye. Ocular-infection and severe ocular complication. Best-corrected visual acuity (BCVA) worse than 0.2 decimal. Difficulty in conducting applanation tonometry for the included eye as determined by the doctor. Severe or serious hypersensitivity to prostaglandin analogues or any ingredients used in the study. Use of IOP lowering ophthalmic solutions other than TRAVATAN Z® or oral carbonic anhydrase inhibitor (Diamox, etc.) during the study period. Use of any adrenocorticosteroids during the study (...) Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2013 Clinical Trials

32. Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

ophthalmic steroid or nonsteroidal anti-inflammatory drug (NSAID) within 2 weeks prior to Visit 1 or during the study period. Use of systemic carbonic anhydrase inhibitor within 2 weeks prior to Visit 1 or during the study period. Ocular surgery or ocular laser treatment of any kind within 3 months prior to Visit 1 or during the study period. Any history of glaucoma surgery (laser or non-laser). History of ocular allergy/inflammation and/or severe blepharitis and/or uveitis. Seasonal allergic (...) glaucoma or OH (eg, congenital glaucoma, closed-angle glaucoma, uveitic glaucoma, or pseudoexfoliation syndrome). Pregnancy or lactation. Uncontrolled asthma (defined as asthma that does not respond to the maximum guideline directed therapy). Allergy to prostaglandin analogues or carbonic anhydrase inhibitors. Allergy to benzalkonium chloride. History of moderate or severe renal or hepatic impairment. Participation in any study of an investigational product within 30 days prior to Visit 1 or at any

2013 Clinical Trials

33. Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure. (PubMed)

or oral carbonic anhydrase inhibitor as initial treatment. Intravenous mannitol was administered for presenting IOP > 60 mmHg or IOP > 40 mmHg 2 hours posttreatment in both arms.Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty percent in the medical group and none in the ALPI group required intravenous mannitol. The ALPI group took less time to achieve IOP < 25 mmHg (18.8 ± 7.5 minutes versus 115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction (...) Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure. The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure.Consecutive cases of acute phacomorphic angle closure were randomized to receive ALPI and an intravenous

Full Text available with Trip Pro

2013 Clinical ophthalmology (Auckland, N.Z.) Controlled trial quality: uncertain

34. 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 24-hour Control

2012 Clinical Trials

35. Effectiveness and Tolerance of beta-Blocker/Pilocarpine Combination Eye Drops in Primary Open-Angle Glaucoma and High Intraocular Pressure. (PubMed)

, 70 patients received CBS 341A for 1 year. Intraocular pressure was measured at noon every 4 months. Fifty-three patients had controlled intraocular pressure with CBS 341A alone. Among the other 17 patients, 2 dropped out, 5 had to change their treatment because of disease progression, 6 underwent argon laser trabeculoplasty, 3 required carbonic anhydrase inhibitor, and 1 had trabeculectomy. There were no withdrawals for intolerance. (...) Effectiveness and Tolerance of beta-Blocker/Pilocarpine Combination Eye Drops in Primary Open-Angle Glaucoma and High Intraocular Pressure. A randomized, double-blind, parallel-group study compared the effectiveness and tolerability of three treatments for glaucoma: 2% carteolol/2% pilocarpine fixed-ratio combination (CBS 341A) twice a day, versus a 0.5% timolol/2% pilocarpine fixed combination twice a day versus 2% carteolol twice a day and 2% pilocarpine three times a day. The treatment

2012 Journal of Glaucoma Controlled trial quality: uncertain

36. The Effects of the Water Drinking Test on Intraocular Pressure

Triggerfish Comparison of fluctuation of Intraocular pressures with different class of drugs Other Name: bimatoprost (Lumigan); brinzolamide (azopt) Active Comparator: Carbonic Anhydrase Inhibitor Device: SENSIMED Triggerfish Comparison of fluctuation of Intraocular pressures with different class of drugs Other Name: bimatoprost (Lumigan); brinzolamide (azopt) Outcome Measures Go to Primary Outcome Measures : 24-hour IOP patterns [ Time Frame: 24-hour ] Assess IOP patterns between day and night time (...) of California, San Diego ClinicalTrials.gov Identifier: Other Study ID Numbers: 110903 First Posted: January 11, 2012 Last Update Posted: January 11, 2012 Last Verified: January 2012 Additional relevant MeSH terms: Layout table for MeSH terms Glaucoma Ocular Hypertension Eye Diseases Brinzolamide Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2011 Clinical Trials

37. AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2011 Clinical Trials

38. Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

Perforations Retinal Diseases Eye Diseases Timolol Dorzolamide Ophthalmic Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2010 Clinical Trials

39. Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

Timolol Latanoprost Dorzolamide Ophthalmic Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2010 Clinical Trials

40. Glaucoma: diagnosis and management

intervals. [2017] [2017] 1.5.5 Offer another pharmacological treatment to people with an IOP of 24 mmHg or more who cannot tolerate their current treatment. The first choice should be an alternative generic PGA, if available, and if this is not tolerated, offer a beta-blocker. If none of these options are tolerated, offer non-generic PGA, carbonic anhydrase inhibitors, sympathomimetics, miotics or a combination of treatments. [2017] [2017] 1.5.6 Offer a drug from another therapeutic class (beta-blocker (...) , carbonic anhydrase inhibitor [4] or sympathomimetic) to people with an IOP of 24 mmHg or more whose current treatment is not reducing IOP sufficiently to prevent the risk of progression to sight loss. T opical drugs from different therapeutic classes may be needed at the same time to control IOP . [2009, amended 2017] [2009, amended 2017] 1.5.7 Refer people whose IOP cannot be reduced sufficiently with pharmacological Glaucoma: diagnosis and management (NG81) © NICE 2019. All rights reserved. Subject

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>